Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University Hospital, Geneva
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04109755CT.gov Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer | — | Recruiting | — | — | — |
NCT03745326CT.gov Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | — | Terminated | — | — | — |
NCT03190941CT.gov Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | — | Recruiting | — | — | — |
NCT02586610CT.gov Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | — | Withdrawn | — | — | — |
NCT02933944CT.gov Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer | — | Terminated | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT01507103CT.gov Tecemotide (L-BLP25) in Rectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | University Hospital, Geneva | P2 | B · 60 |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P4 | BBB |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Fluorouracilum | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Cetuximab | Tang-Du Hospital | P2 | BB |
| Panitumumab | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
+42 more in the Rectal Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Rectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-rectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →